Wolfgang Wick

Research interests

Publications

• Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

  New England Journal of Medicine · 2023 · 10.1056/nejmoa2304194

• Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.10.001

• Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

  Neuro-Oncology · 2020 · https://doi.org/10.1093/neuonc/noaa106

• How to use and assess qualitative research methods

  Neurological Research and Practice · 2020 · 10.1186/s42466-020-00059-z

• EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

  Nature Reviews Clinical Oncology · 2020 · https://doi.org/10.1038/s41571-020-00447-z

• Glutamatergic synaptic input to glioma cells drives brain tumour progression

  Nature · 2019 · 10.1038/s41586-019-1564-x

• Actively personalized vaccination trial for newly diagnosed glioblastoma

  Nature · 2018 · 10.1038/s41586-018-0810-y

• DNA methylation-based classification of central nervous system tumours

  Nature · 2018 · 10.1038/nature26000

• DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30155-9

• Lomustine and Bevacizumab in Progressive Glioblastoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1707358

• Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30517-x

• European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30194-8

• Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1611977

• Glioma

  Nature Reviews Disease Primers · 2015 · 10.1038/nrdp.2015.17

• Brain tumour cells interconnect to a functional and resistant network

  Nature · 2015 · 10.1038/nature16071

• MGMT testing—the challenges for biomarker-based glioma treatment

  Nature Reviews Neurology · 2014 · 10.1038/nrneurol.2014.100

• Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1308345

• EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70011-7

• Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70379-1

• Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1308345

• Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

  The Lancet Oncology · 2012 · 10.1016/s1470-2045(12)70164-x

• Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma

  Cancer Cell · 2012 · https://doi.org/10.1016/j.ccr.2012.08.024

• An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

  Nature · 2011 · https://doi.org/10.1038/nature10491

• An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

  Nature · 2011 · 10.1038/nature10491

• Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

  Acta Neuropathologica · 2010 · 10.1007/s00401-010-0781-z

• Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2009.26.3541

• Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.26.3541

• NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2009.23.6497

• Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

  Acta Neuropathologica · 2009 · 10.1007/s00401-009-0561-9

• MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

  Nature Reviews Neurology · 2009 · 10.1038/nrneurol.2009.197

• Correlation of O 6 -Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.11.5964

Current projects

No projects listed.